BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26765054)

  • 1. Limitations of Ber-EP4 for distinction of Bowen disease from basal cell carcinoma.
    Kogut M; Toberer F; Enk AH; Hassel JC
    J Cutan Pathol; 2016 Apr; 43(4):367-71. PubMed ID: 26765054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ber-EP4 is a useful marker for follicular germinative cell differentiation of cutaneous epithelial neoplasms.
    Ansai S; Takayama R; Kimura T; Kawana S
    J Dermatol; 2012 Aug; 39(8):688-92. PubMed ID: 22300237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pagetoid squamous cell carcinoma in situ (pagetoid Bowen's disease) of the external genitalia.
    Raju RR; Goldblum JR; Hart WR
    Int J Gynecol Pathol; 2003 Apr; 22(2):127-35. PubMed ID: 12649666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthokeratotic Bowen disease: a histopathologic, immunohistochemical and molecular study.
    Idriss MH; Misri R; Böer-Auer A
    J Cutan Pathol; 2016 Jan; 43(1):24-31. PubMed ID: 26272630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ber-EP4 immunoreactivity in normal skin and cutaneous neoplasms.
    Jimenez FJ; Burchette JL; Grichnik JM; Hitchcock MG
    Mod Pathol; 1995 Oct; 8(8):854-8. PubMed ID: 8552575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokeratin 17 immunoexpression in actinic keratosis (bowenoid and nonbowenoid) and in Bowen disease.
    Fernandez-Flores A
    Ann Diagn Pathol; 2016 Feb; 20():1-6. PubMed ID: 26740287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P27 and mib1 expression in actinic keratosis, Bowen disease, and squamous cell carcinoma.
    Oh CW; Penneys N
    Am J Dermatopathol; 2004 Feb; 26(1):22-6. PubMed ID: 14726819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-situ squamous cell carcinoma (Bowen's disease) with divergent adnexal differentiation.
    Slater DN; Parsons MA; Mudhar H
    Histopathology; 2003 Jul; 43(1):100. PubMed ID: 12823722
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma.
    Fan YS; Carr RA; Sanders DS; Smith AP; Lazar AJ; Calonje E
    Histopathology; 2007 Jul; 51(1):80-6. PubMed ID: 17593083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic changes after photodynamic therapy for Basal cell carcinoma and Bowen disease: a histologic and immunohistochemical investigation.
    Fantini F; Greco A; Cesinaro AM; Surrenti T; Peris K; Vaschieri C; Marconi A; Giannetti A; Pincelli C
    Arch Dermatol; 2008 Feb; 144(2):186-94. PubMed ID: 18283175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin.
    Tellechea O; Reis JP; Domingues JC; Baptista AP
    Am J Dermatopathol; 1993 Oct; 15(5):452-5. PubMed ID: 8238781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma.
    Krahl D; Sellheyer K
    J Cutan Pathol; 2007 Oct; 34(10):782-7. PubMed ID: 17880584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ber-EP4-positive phenotype differentiates actinic keratosis from superficial basal cell carcinoma.
    Tope WD; Nowfar-Rad M; Kist DA
    Dermatol Surg; 2000 May; 26(5):415-8. PubMed ID: 10816226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 expression in Bowen's disease and in microinvasive squamous cell carcinoma of the skin.
    Hughes JH; Robinson RA
    Mod Pathol; 1995 Jun; 8(5):526-9. PubMed ID: 7675772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous squamous cell carcinoma, Bowen's disease and basal cell carcinoma.
    Chen SY; Takeuchi S; Moroi Y; Hayashida S; Kido M; Chen SJ; Tomoeda H; Uenotsuchi T; Tu YT; Furue M; Urabe K
    J Dermatol Sci; 2008 Sep; 51(3):210-5. PubMed ID: 18547788
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of L-type amino acid transporter 1 in various skin lesions.
    Hirano K; Uno K; Kuwabara H; Kojima K; Ohno S; Sakurai H; Kamma H; Kurata A
    Pathol Res Pract; 2014 Oct; 210(10):634-9. PubMed ID: 24939142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of promyelocytic leukaemia protein in Bowen's disease, skin squamous cell carcinoma and basal cell carcinoma].
    Wang Q; Ma H; Wang S; Ma Y; Zou X; Li R
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jul; 33(7):1075-7. PubMed ID: 23895857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens.
    Swanson PE; Fitzpatrick MM; Ritter JH; Glusac EJ; Wick MR
    J Cutan Pathol; 1998 Mar; 25(3):153-9. PubMed ID: 9550314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of cell proliferation in benign, premalignant and malignant skin lesions.
    Bordbar A; Dias D; Cabral A; Beck S; Boon ME
    Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):229-35. PubMed ID: 17525640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratin 10-negative nested pattern enables sure distinction of clonal seborrheic keratosis from pagetoid Bowen's disease.
    Böer-Auer A; Jones M; Lyasnichaya OV
    J Cutan Pathol; 2012 Feb; 39(2):225-33. PubMed ID: 22236073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.